Global Biosimilars Market Revenue and Share Analysis Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilars market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Biosimilars Market In The Period 2029-2034?

The biosimilars market size has experienced rapid expansion in recent years. Projections indicate it will expand from $18.65 billion in 2024 to $21.85 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.2%. This historical growth is due to several factors, including a rise in cancer prevalence, robust economic growth in developing markets, increased spending on pharmaceutical research and development, higher healthcare expenditure, expanding government initiatives, a strong drug development pipeline, the economical nature of biosimilars, and an uptick in patent expirations.

The biosimilars market is projected to expand significantly in the coming years. Its valuation is anticipated to reach $41.34 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.3%. This expansion during the forecast period is propelled by several factors, including the rising incidence of cancer, a greater need for prophylaxis using granulocyte colony-stimulating factor (G-CSF), higher healthcare spending, the considerable potential of developing economies, advancements in technology, widespread adoption of biological drugs, an aging global demographic, and improved access to healthcare services. Key trends identified for the forecast timeframe encompass a strong emphasis on extensive research and development for creating impactful and novel medications, prioritizing mergers and acquisitions as a growth tactic, forging strategic alliances, boosting investments, and integrating artificial intelligence.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Strategic Drivers Are Accelerating The Biosimilars Market Expansion?

The increasing incidence of chronic illnesses such as arthritis, asthma, and cancer is expected to serve as a primary impetus for the biosimilars market. Extended work hours, insufficient physical activity, and unhealthy dietary and drinking habits contribute to the prevalence of these chronic diseases, and biosimilars are being increasingly utilized for their treatment. Biosimilars function by activating the immune system’s response against cancer cells, thereby aiding the body in their removal. A United Nations article suggests that by 2030, the percentage of global deaths attributed to chronic diseases is projected to rise to 70% of total deaths. The global burden of chronic disease is anticipated to reach approximately 60%. Thus, the escalating prevalence of chronic diseases is foreseen to boost the demand for biosimilars, consequently driving the biosimilars market.

What Is The Detailed Segment Distribution Of The Biosimilars Market?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

How Are Global Trends Impacting The Development Of The Biosimilars Market?

Leading firms within the biosimilars market prioritize the creation of innovative products to secure a competitive advantage. AMJEVITA stands as the initial U.S. biosimilar for Humira, a medication utilized by over a million individuals suffering from specific severe inflammatory conditions. For example, Amgen Inc., a US-based biotechnology firm, introduced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), in January 2023, and it is presently accessible in the US. AMJEVITA (40 mg) can be obtained at a list price (wholesale acquisition cost) that is 55% lower than Humira’s current list price. Furthermore, AMJEVITA is additionally offered at a list price 5% beneath Humira’s present list price.

Who Are The Major Stakeholders Operating In The Biosimilars Market?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2025, By The Business Research Company

Biosimilar Growth Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Biosimilar Therapeutic Peptide Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795